1
Participants
Start Date
April 23, 2025
Primary Completion Date
May 28, 2025
Study Completion Date
May 28, 2025
Tozinameran (BNT162b2)
"1. 12 years or older~ * Primary series: 2 doses, 30 μg each, administered 21 days apart~ * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~ * Primary series: 2 doses, 10 μg each, administered 21 days apart~ * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~ * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)"
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
"1\. 12 years or older~\- Single booster dose, 15/15 μg, administered after ≥3 months after primary series"
Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
"1\. 12 years or older~\- Single booster dose, 15/15 μg administered after ≥3 months after primary series"
Pfizer, Seoul
Lead Sponsor
Pfizer
INDUSTRY